ZA201009165B - Melanocortin receptor-specific peptides for treatment of sexual dysfunction - Google Patents

Melanocortin receptor-specific peptides for treatment of sexual dysfunction

Info

Publication number
ZA201009165B
ZA201009165B ZA2010/09165A ZA201009165A ZA201009165B ZA 201009165 B ZA201009165 B ZA 201009165B ZA 2010/09165 A ZA2010/09165 A ZA 2010/09165A ZA 201009165 A ZA201009165 A ZA 201009165A ZA 201009165 B ZA201009165 B ZA 201009165B
Authority
ZA
South Africa
Prior art keywords
treatment
sexual dysfunction
melanocortin receptor
specific peptides
peptides
Prior art date
Application number
ZA2010/09165A
Other languages
English (en)
Inventor
Yi-Qun Shi
Shubh D Sharma
Wei Yang
Xin Chen
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of ZA201009165B publication Critical patent/ZA201009165B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA2010/09165A 2008-06-09 2010-12-21 Melanocortin receptor-specific peptides for treatment of sexual dysfunction ZA201009165B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5991008P 2008-06-09 2008-06-09
PCT/US2009/046571 WO2009152079A1 (en) 2008-06-09 2009-06-08 Melanocortin receptor-specific peptides for treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
ZA201009165B true ZA201009165B (en) 2012-03-28

Family

ID=41417081

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/09165A ZA201009165B (en) 2008-06-09 2010-12-21 Melanocortin receptor-specific peptides for treatment of sexual dysfunction

Country Status (14)

Country Link
US (2) US8487073B2 (cg-RX-API-DMAC7.html)
EP (1) EP2300036B1 (cg-RX-API-DMAC7.html)
JP (1) JP5628796B2 (cg-RX-API-DMAC7.html)
KR (1) KR101687037B1 (cg-RX-API-DMAC7.html)
CN (1) CN102131514B (cg-RX-API-DMAC7.html)
AU (1) AU2009257631B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0909947A2 (cg-RX-API-DMAC7.html)
CA (1) CA2727317C (cg-RX-API-DMAC7.html)
EA (1) EA018630B1 (cg-RX-API-DMAC7.html)
IL (1) IL209867A (cg-RX-API-DMAC7.html)
MX (1) MX2010013436A (cg-RX-API-DMAC7.html)
NZ (1) NZ590254A (cg-RX-API-DMAC7.html)
WO (1) WO2009152079A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201009165B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018630B1 (ru) 2008-06-09 2013-09-30 Палатин Текнолоджиз, Инк. Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
NZ596617A (en) * 2009-06-08 2014-04-30 Palatin Technologies Inc Melanocortin receptor-specific peptides
CN102712674A (zh) 2009-11-23 2012-10-03 帕拉丁科技公司 黑皮质素-1受体-特异性的线性肽
NZ599774A (en) 2009-11-23 2014-11-28 Palatin Technologies Inc Melanocortin-1 receptor-specific cyclic peptides
PT3539551T (pt) 2011-12-29 2021-11-04 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos
CN102702330B (zh) * 2012-03-01 2015-04-01 张嘎 环状核心序列与生物素或穿膜肽相连而成的促黑激素类似物
EP2814501A4 (en) * 2012-03-13 2016-03-02 Tensive Controls Inc MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
WO2014071339A2 (en) 2012-11-05 2014-05-08 Palatin Technologies, Inc. Uses of bremelanotide in therapy for female sexual dysfunction
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
AU2016330773A1 (en) 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
RU2655763C2 (ru) * 2016-10-24 2018-05-29 Общество С Ограниченной Ответственностью "Айвикс" Фармацевтическая композиция и способ лечения женских сексуальных дисфункций
WO2019195756A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
CN115279390A (zh) * 2020-02-03 2022-11-01 帕拉丁科技公司 反向酰胺连接的促黑素受体特异性环状肽

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
EP0292291B1 (en) 1987-05-22 1994-08-10 University Patents, Inc. Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6100048A (en) * 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
WO1994022460A1 (en) 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US7396814B2 (en) * 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
CA2158425C (en) 1995-09-15 2003-01-28 Mac E. Hadley Diagnostic and treatment of erectile dysfunction
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
EP0946595A2 (en) 1996-12-17 1999-10-06 Quadrant Holdings Cambridge Limited Melanocortins
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
SE9801571D0 (sv) * 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US6887846B2 (en) * 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
TR200102765T2 (tr) * 1999-03-29 2002-05-21 The Procter & Gamble Company Melanokortin reseptör ligandları
WO2003006620A2 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) * 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US20030064921A1 (en) * 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
US6693165B2 (en) * 2000-01-18 2004-02-17 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
AU2001261363A1 (en) 2000-05-09 2001-11-20 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
MXPA03001721A (es) 2000-08-30 2003-05-27 Hoffmann La Roche Peptidos ciclicos selectivos.
HUP0303085A2 (hu) 2000-09-27 2003-12-29 The Procter & Gamble Co. Melanokortin receptor ligandumok és ezeket tartalmazó gyógyszerkészítmények
US20030113263A1 (en) * 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
EP1409521A2 (en) 2001-07-12 2004-04-21 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
EP1469851B1 (en) * 2002-01-23 2006-10-11 Eli Lilly And Company Melanocortin receptor agonists
FR2835528B1 (fr) * 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US7135548B2 (en) * 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
WO2004046166A2 (en) 2002-11-14 2004-06-03 Zengen, Inc. Modified alpha-msh peptides and derivatives thereof
US20050101535A1 (en) * 2003-05-06 2005-05-12 Rosenstein David H. Use of a synthetic alpha-melanocyte stimulating hormone agonist to decrease steroid induced weight gain
KR20060026011A (ko) * 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
EP1625158A2 (en) 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
EP1644023A2 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
US7084111B2 (en) * 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
WO2005019212A1 (en) 2003-08-20 2005-03-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
JP5230941B2 (ja) 2003-11-24 2013-07-10 クリヌベール、ファーマスーティカルズ、リミテッド Ｍｃ１ｒ変異対立遺伝子を有するヒトにおいてメラニン形成を誘導する方法
WO2005060985A1 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
US20070123453A1 (en) * 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
CN1563076A (zh) 2004-04-02 2005-01-12 西南生物工程产业化中试基地有限公司 一种用于治疗性功能障碍的α－MSH类似物及制备方法
NZ582130A (en) 2004-08-04 2011-11-25 Clinuvel Pharmaceuticals Ltd Methods of inducing melanogenesis in a subject
TW200626611A (en) 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
EP2939686A1 (en) 2004-10-08 2015-11-04 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
EP1812046B1 (en) * 2004-10-25 2011-03-16 Centocor Ortho Biotech Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
WO2006048451A1 (en) 2004-11-04 2006-05-11 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2006048449A2 (en) 2004-11-04 2006-05-11 Novo Nordisk A/S Mc4r selective peptides and their use in the treatment of obesity
US20110098213A1 (en) 2004-11-04 2011-04-28 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
JP2008519009A (ja) 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
WO2006060873A1 (en) 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US7563781B2 (en) 2005-01-14 2009-07-21 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives
US20080207493A1 (en) 2005-03-17 2008-08-28 Novo Nordisk A/S Compounds for Use in the Treatment of Obesity
AU2006253733A1 (en) 2005-05-31 2006-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Backbone cyclized melanocortin stimulating hormone (alpha S ) analogs
CN105837661B (zh) 2005-07-08 2024-10-15 益普生制药股份有限公司 黑皮质素受体配体
CN101528250A (zh) 2005-07-08 2009-09-09 研究及应用科学协会股份有限公司 黑皮质素受体的配体
CN1709906A (zh) 2005-07-15 2005-12-21 中国科学技术大学 α－促黑激素的环状类似肽及其应用
KR20080031414A (ko) 2005-07-18 2008-04-08 노보 노르디스크 에이/에스 비만치료에 사용하기 위한 신규 펩티드
US20080227693A1 (en) 2005-08-29 2008-09-18 Palatin Technologies, Inc. Cyclic Peptide Isolation by Spray Drying
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
US20100056433A1 (en) 2007-01-18 2010-03-04 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
EP2104684A1 (en) 2007-01-18 2009-09-30 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2008087189A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
FR2914646A1 (fr) 2007-04-04 2008-10-10 Neorphys Soc Par Actions Simpl Analogues peptidiques des recepteurs des melanocortines
US20100173834A1 (en) 2007-06-15 2010-07-08 Zheng Xin Dong Cyclic peptide melanocortin receptor ligands
EA018630B1 (ru) * 2008-06-09 2013-09-30 Палатин Текнолоджиз, Инк. Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции
WO2009151383A1 (en) 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina

Also Published As

Publication number Publication date
WO2009152079A1 (en) 2009-12-17
JP5628796B2 (ja) 2014-11-19
EP2300036B1 (en) 2017-04-05
US8487073B2 (en) 2013-07-16
EA201001722A1 (ru) 2011-08-30
BRPI0909947A2 (pt) 2017-06-27
IL209867A (en) 2015-08-31
US20110065652A1 (en) 2011-03-17
EP2300036A1 (en) 2011-03-30
EA018630B1 (ru) 2013-09-30
IL209867A0 (en) 2011-02-28
MX2010013436A (es) 2011-06-21
EP2300036A4 (en) 2012-01-18
JP2011522839A (ja) 2011-08-04
CN102131514B (zh) 2014-08-20
AU2009257631B2 (en) 2014-07-24
CA2727317A1 (en) 2009-12-17
KR20110040819A (ko) 2011-04-20
CN102131514A (zh) 2011-07-20
NZ590254A (en) 2012-07-27
US8729224B2 (en) 2014-05-20
AU2009257631A1 (en) 2009-12-17
KR101687037B1 (ko) 2016-12-15
US20130288987A1 (en) 2013-10-31
CA2727317C (en) 2015-02-17

Similar Documents

Publication Publication Date Title
IL209867A0 (en) Melanocortin receptor-specific peptides for treatment of sexual dysfunction
ZA201101127B (en) Treatment of tailings streams
PL2349106T3 (pl) System do leczenia męskiej dysfunkcji seksualnej
HUE056278T2 (hu) Elhízás kezelése
IL208354A0 (en) Methods of treatment
IL216451A0 (en) Melanocortin receptor-specific peptides
EP2389388A4 (en) TREATMENT OF OBESITY
IL216843A (en) Melanocortin receptor-specific peptides
IL213502A0 (en) Treatment of dyskinesia related disorders
PL2496596T3 (pl) Peptydy terapeutyczne
IL215562A0 (en) Process for isolating therapeutic peptide
WO2009129357A9 (en) Method of treating erectile dysfunction
EP2436359A4 (en) GODEMICHÉ FOR SEXUAL STIMULATION
EP2350641A4 (en) Methods of Treatment
EP2405929A4 (en) TREATMENT PROCEDURE FOR AUTOIMMUNE DISEASES
IL241253A0 (en) Peptides for the treatment of neurodegenerative diseases
EP2346443A4 (en) SEXUAL ASSISTANCE SYSTEM
GB0724953D0 (en) Methods of peptide modification
EP2164494A4 (en) Methods of Treatment
GB0908101D0 (en) Treatment of stress
SI2340035T1 (sl) Zdravljenje melabsorbcije fruktoze
EP2254901A4 (en) THERAPEUTIC PEPTIDES
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
EP2212701A4 (en) NEW TREATMENT OF AUTOIMMUNE DISEASES
GB2460445B (en) Treatment of ringworm